BEIJING, Aug. 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 ("1Q FY2011") today.1Q FY2011 HighlightsFor the Three Months EndedJune 30, 2010June 30, 2011June 30, 2011RMBRMBUS$% change(in thousands except for per ADS information)Net revenues186,170237,11136,68527.4%Net income33,67835,7285,5286.1%Diluted earnings per ADS*1.291.350.214.7%Non-GAAP net income57,01190,45213,99558.7%Non-GAAP diluted earnings per ADS*2.183.420.5356.9%Adjusted EBITDA105,152154,28923,87146.7%For the Three Months EndedMarch 31, 2011June 30, 2011June 30, 2011RMBRMBUS$% change(in thousands)Net cash provided by operating activities37,33962,2439,63066.7%As ofMarch 31, 2011June 30, 2011June 30, 2011RMBRMBUS$% change(in thousands)Cash and cash equivalents1,123,8181,239,458191,76310.3%Trade accounts receivable, net481,096565,06187,42217.5%Convertible notes2,752,3042,669,914413,076(3.0)%Outlook for second fiscal quarter ending September 30, 2011For the Three Months Ending September 30, 2011Year over YearRMBUS$% change(in millions except for per ADS information)Target net revenues238.0 – 240.036.8 – 37.117.9 – 18.9%Target non-GAAP net income82.0 – 84.012.7 – 13.025.4 – 28.4%Target non-GAAP diluted earnings per ADS*3.07 – 3.150.47 – 0.4922.8 – 26.0%Outlook for the full fiscal year ending March 31, 2012For the Fiscal Year Ending March 31, 2012Year over YearRMBUS$% change(in millions except for per ADS information)Target net revenues970.0 – 995.0150.1 – 153.915.2 – 18.1%Target non-GAAP net income315.0 – 325.048.7 – 50.315.4 – 19.0%Target non-GAAP diluted earnings per ADS*11.75 – 12.131.82 – 1.8813.1 – 16.7%The above targets are based on the Company's current views on operating and market conditions, which are subject to change.
*One American Depositary Share ("ADS") = 10 ordinary shares
See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.
"We have recently implemented the first steps of two new initiatives which will support our long term growth," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We have established a collaboration with Da An Health for our domestic market as well as a collaboration with Leica Microsystems for both the domestic and the international markets. Da An Health is a fast growing independent laboratory service network serving mainly small and mid-size hospitals in China. We believe this collaboration will help us penetrate over time a new and big customer group for our molecular diagnostic products in a cost effective way. The collaboration with Leica Microsystems is to implement our strategy to enter the international market for our products through partnerships with leading global players. The partnership with Leica Microsystems substantially reduces our business risks and costs associated with entering the international market considering the complicated regulatory approval processes, medical reimbursement conditions and distribution channels in different countries and regions. The joint research and development with Leica Microsystems to automate our FISH probes on Leica's BOND system is important for the high volume users such as independent laboratory service networks in major global markets as well as existing and potential high volume hospital users in China. We are working closely with our new partners to realize the value of these collaborations for all of us. Meanwhile, we are also in discussion with a number of leading global players for different types of collaborations for our other molecular diagnostic products."
"Our DSO increased in recent quarters due to slower payment from some of our ECLIA distributors and the change in our sales mix," commented Mr. Sam Tsang, Chief Financial Officer of the Company. "ECLIA distributors normally pay in about 3 months but some of them took longer time to pay in the past few quarters. Slower payments from distributors indicate a possible risk of bad debt, and we have recently taken measures to control this risk including lowering credit limit for certain slow paying distributors and control over the order fulfillment for these distributors according to their payments. Meanwhile, we are adding new distributors to diversify the risk. The change in sales mix relates to the increasing portion of our revenues from our molecular diagnostic products which we sell to hospitals directly. These hospitals normally pay us in 6 to 12 months and the bigger the hospital, the longer the payment cycle. However, we consider the risk of bad debt from these hospitals to be very low considering that they are tier 1 hospitals, have a strong financial position and are government-owned. Recently, we have increased compensation of our direct sales personnel based on collection from hospitals to increase incentive for collection. On the other hand, despite the increase in DSO in the past few quarters, we still generated sizeable cash flows from operations. We expect our DSO to become stable and decline in the coming quarters."
"We are confident in handling our convertible debts before maturity," further commented Mr. Sam Tsang. "The nearest maturity of convertible debts is approximately US$17 million in November this year which is a small amount considering our cash position of approximately US$192 million. The next maturity of approximately US$247 million of convertible debts will be in August 2013. We believe that our current cash position, our future free cash flows and our access to other sources of funds such as commercial banks in China will provide sufficient liquidity to pay off the debts before maturity. We have noticed that the debts have been trading at a substantial discount which is favorable to us."
1Q FY2011 Unaudited Financial ResultsThe Company reported net revenues of RMB237.1 million (US$36.7 million) for 1Q FY2011, representing a 27.4% increase from the corresponding period of FY2010.
The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment mainly includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.
Molecular diagnostic system sales for 1Q FY2011 were RMB156.1 million (US$24.2 million), representing a 44.5% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in usage of the Company's FISH probes by hospitals as well as the significant increase in sales of SPR-based HPV-DNA chips to hospitals during 1Q FY2011.
Immunodiagnostic system sales for 1Q FY2011 were RMB81.0 million (US$12.5 million), representing a 3.7% increase from the corresponding period of FY2010.
Gross margin was 62.9% for 1Q FY2011 which decreased year-over-year from 67.0% for the corresponding period of FY2010. The year-over-year decrease was primarily due to the reclassification of amortization of SPR intangible assets from operating expenses to cost of revenues after the commencement of sales of HPV-DNA chips in 2Q FY2010. Such factor was partially offset by the positive impact of more contribution from the sales of FISH probes and HPV-DNA chips which generate higher gross margin and a decrease in the number of free ECLIA analyzers provided to distributors and free SPR analyzers provided to hospitals. Non-GAAP gross margin was 83.1% for 1Q FY2011 which increased year-over-year from 79.1% for the corresponding period of FY2010. The year-over-year increase in non-GAAP gross margin was primarily due to more contribution from the sales of FISH probes and HPV-DNA chips and the decrease in free ECLIA analyzers and SPR analyzers as noted above.
Research and development expenses were RMB10.8 million (US$1.7 million) for 1Q FY2011, representing a 1.1% year-over-year increase. The year-over-year increase was primarily due to an increase in salaries of research personnel offset by a decrease in stock compensation expense. Non-GAAP research and development expenses were RMB9.7 million (US$1.5 million) for 1Q FY2011, representing a 5.3% year-over-year increase. The year-over-year increase was primarily due to the increase in salaries of research personnel.
Sales and marketing expenses were RMB23.3 million (US$3.6 million) for 1Q FY2011, representing a 27.4% year-over-year increase. Non-GAAP sales and marketing expenses were RMB23.0 million (US$3.6 million) for 1Q FY2011, representing a 26.5% year-over-year increase. The year-over-year increases were primarily due to an increase in direct sales efforts for molecular diagnostic systems.
General and administrative expenses were RMB22.6 million (US$3.5 million) for 1Q FY2011, representing a 10.1% year-over-year decrease. The year-over-year decrease was primarily due to a decrease in stock compensation expense. Non-GAAP general and administrative expenses were RMB16.3 million (US$2.5 million) for 1Q FY2011, representing a 1.4% year-over-year increase.
Interest expense on convertible notes was RMB33.3 million (US$5.2 million) for 1Q FY2011. Non-GAAP interest expense on convertible notes was RMB32.4 million (US$5.0 million) for 1Q FY2011. As of June 30, 2011, the Company's outstanding convertible notes of US$16.7 million, US$246.5 million and US$150.0 million in principal value bear interest at 3.5%, 4% and 6.25% per annum, respectively, and will mature in November 2011, August 2013 and December 2016, respectively.
Interest expense related to amortization of convertible notes issuance costs was RMB4.0 million (US$0.6 million) for 1Q FY2011.
Interest expense related to amortization of share lending costs was RMB2.3 million (US$0.4 million) for 1Q FY2011.
Other income was RMB4.8 million (US$0.7 million) for 1Q FY2011, representing a 88.9% year-over-year decrease. The significant year-over-year decrease was primarily due to a decrease in gain on repurchase of convertible notes.
Income tax expense was RMB29.3 million (US$4.5 million) for 1Q FY2011. The high effective tax rate was due to the fact that certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China which the Company does not intend to permanently reinvest in China.
Net income was RMB35.7 million (US$5.5 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes. Non-GAAP net income was RMB90.5 million (US$14.0 million) for 1Q FY2011, representing a 58.7% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales and other reasons mentioned above.
Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB150.6 million (US$23.3 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes.
Adjusted EBITDA was RMB154.3 million (US$23.9 million) for 1Q FY2011, representing a 46.7% increase from the corresponding period of FY2010. The increase was primarily due to increased sales in 1Q FY2011.
Stock compensation expense for 1Q FY2011 was RMB7.8 million (US$1.2 million), of which RMB0.2 million was allocated to cost of revenues, RMB1.0 million to research and development expenses, RMB0.3 million to sales and marketing expenses and RMB6.3 million to general and administrative expenses.
Amortization of acquired intangible assets for 1Q FY2011 was RMB47.7 million (US$7.4 million) which was all allocated to cost of revenues.
As of June 30, 2011, the Company's cash and cash equivalents were RMB1,239.5 million (US$191.8 million). Net cash generated from operating activities for 1Q FY2011 was RMB62.2 million (US$9.6 million). Net cash generated from investing activities for 1Q FY2011 was RMB96.7 million (US$15.0 million). Net cash used in financing activities for 1Q FY2011 was RMB41.6 million (US$6.4 million).
As of June 30, 2011, the Company's net accounts receivable was RMB565.1 million (US$87.4 million), representing an increase of 17.5% from the balance at March 31, 2011. The increase in net accounts receivable was primarily due to the increase in molecular diagnostic system sales to hospital customers which normally pay in 6 to 12 months and the slower payments from certain distributors of immunodiagnostic systems.
The Company evaluates the collectability of its accounts receivable based on the aging of account balances, collection history, credit quality of the customer and current economic conditions that may affect a customer's ability to pay. The Company has recognized an allowance for doubtful accounts in its consolidated financial statements. The allowance for doubtful accounts increased by RMB2.4 million (US$0.4 million) to RMB28.8 million (US$4.4 million) as of June 30, 2011 from RMB26.4 million as of March 31, 2011.
For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, June 30, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on June 30, 2011 or at any other dates.
Non-GAAP Measure DisclosuresThe Company reported its operating results in accordance with U.S. generally accepted accounting principles ("GAAP") for the three months ended June 30, 2010 and 2011. The Company also presented non-GAAP information, which included EBITDA and adjusted EBITDA, for the three months ended June 30, 2010 and 2011. The non-GAAP measures are defined below:
Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management believes they reflect the Company's ongoing business in a manner that allows meaningful period-to-period comparison. The Company's management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company's current operating performance and future prospects in the same manner as management does, if they so choose.
The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.
Conference CallThe Company's senior management team will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on August 16, 2011 (or 8:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.
The dial-in details for the live conference call are as follows:
-- U.S. Toll Free Number 1-866-783-2141
-- International Dial-in Number 1-857-350-1600
A live webcast of the conference call will be available on http://ir.chinameditech.com.
A replay of this webcast will be available for one month on this website.
A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on August 17, 2011.
The dial-in details for the replay are as follows:
-- U.S. Toll Free Number 1-888-286-8010
-- International Dial-in Number 1-617-801-6888
About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.
Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release, as well as its outlook for the second fiscal quarter ending September 30, 2011 and full fiscal year ending March 31, 2012, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
ContactsSam Tsang and Winnie YamTel: +852-2511-9808Email: IR@chinameditech.comChina Medical Technologies, Inc.Unaudited Condensed Consolidated Balance SheetsAs ofMarch 31, 2011June 30, 2011RMBRMBUS$(in thousands)AssetsCurrent assetsCash and cash equivalents
1,123,8181,239,458191,763Trade accounts receivable, net (1)481,096565,06187,422Inventories
19,27320,3153,143Prepayments and other receivables
18,95212,8331,986Due from a related party
98,225--Total current assets
1,741,3641,837,667284,314Property, plant and equipment, net
139,448134,56220,819Land use rights
8,6548,6541,339Intangible assets, net
2,973,3582,891,353447,335Convertible notes issuance costs
55,81751,1487,913Share lending costs
4,948,0624,949,999765,838Liabilities Current liabilitiesTrade accounts payable
44,50251,5757,979Accrued liabilities and other payables
146,081107,13616,576Income taxes payable
77,95491,93914,224Total current liabilities
2,606,2232,562,778396,500Deferred income taxes
3,157,4763,118,673482,505Shareholders' equityOrdinary shares US$0.1 par value:500,000,000 authorized; 322,680,001 issued and
outstanding as of March 31, 2011 and June 30, 2011
258,840258,84040,046Additional paid-in capital
(201,362)(201,362)(31,154)Accumulated other comprehensive loss
934,953970,681150,179Total shareholders' equity
1,790,5861,831,326283,333Total liabilities and shareholders' equity
4,948,0624,949,999765,838Note:As ofMarch 31, 2011June 30, 2011RMB'000RMB'000US$'000(1)
Trade accounts receivable
507,482593,81491,871Allowance for doubtful accounts
(26,386)(28,753)(4,449)Trade accounts receivable, net481,096565,06187,422China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresFor the Three Months EndedFor the Three Months EndedJune 30, 2010June 30, 2011GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRMBRMBRMBRMBRMBRMB(in thousands except for per ADS information)Net revenues (1)
186,170-186,170237,111-237,111Cost of revenues (2)
124,81622,466147,282149,23147,920197,151Operating expenses Research and
(10,632)1,418(9,214)(10,752)1,048(9,704)Sales and marketing (3)
(27,329)27,329----Total operating expenses
4,597-4,5977,336-7,336Interest expense –
convertible notes (5)
(32,505)7,916(24,589)(33,347)990(32,357)Interest expense –
amortization of convertible
notes issuance costs
(4,012)-(4,012)(4,007)-(4,007)Interest expense –
share lending costs (6)
(2,475)2,475-(2,343)2,343-Other income (expense),
52,34023,33375,67365,03654,724119,760Income tax expense
33,67823,33357,01135,72854,72490,452Earnings per ADS- basic (8)
1.300.892.191.362.083.44- diluted (8)
1.290.892.181.352.073.42Weighted average number of ADS- basic (8)
26,005,975-26,005,97526,300,264-26,300,264- diluted (8)
26,128,403-26,128,40326,485,024-26,485,024China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresConvenience Translation for Reference OnlyFor the Three Months EndedJune 30, 2011GAAPAdjustmentsNon-GAAPUS$US$US$(in thousands except for per ADS information)Net revenues (1)
36,685-36,685Cost of revenues (2)
23,0887,41430,502Operating expensesResearch and development (3)
(1,664)163(1,501)Sales and marketing (3)
(3,599)41(3,558)General and administrative (3)
(3,498)970(2,528)Amortization of SPR intangible assets (4)
---Total operating expenses
1,135-1,135Interest expense – convertible notes (5)
(5,159)153(5,006)Interest expense – amortization of
convertible notes issuance costs
(620)-(620)Interest expense – amortization of
share lending costs (6)
(363)363-Other income (expense), net (7)
742(637)105Income before income tax
10,0628,46718,529Income tax expense
5,5288,46713,995Earnings per ADS- basic (8)
0.210.320.53- diluted (8)
0.210.320.53Weighted average number of ADS- basic (8)
26,300,264-26,300,264- diluted (8)
26,485,024-26,485,024For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, June 30, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on June 30, 2011 or at any other dates.Notes:For the Three Months EndedJune 30, 2010June 30, 2011(1)
RMB'000RMB'000US$'000- Molecular diagnostic systems
108,092156,14424,158- Immunodiagnostic systems
78,07880,96712,527186,170237,11136,685Molecular diagnostic systems - HPV-DNA chips1814,0502,174(2) Non-GAAP numbers exclude stock compensation expense and amortization of acquired intangible assets.For the Three Months EndedJune 30, 2010June 30, 2011RMB'000RMB'000US$'000Stock compensation expense
5224338Amortization of acquired intangible assets22,41447,6777,37622,46647,9207,414(3) Non-GAAP numbers exclude stock compensation expense.(4) Non-GAAP numbers exclude amortization of acquired intangible assets.(5) Non-GAAP numbers exclude non-cash interest expense of convertible notes.(6) Non-GAAP numbers exclude interest expense for amortization of share lending costs. (7) Non-GAAP numbers exclude gain on repurchase of convertible notes.For the Three Months EndedJune 30, 2010June 30, 2011RMB'000RMB'000US$'000 Gain on repurchase of convertible notes47,3934,112637(8) Interest expense and amortization in connection with convertible notes were not added back in computing GAAP diluted earnings per ADS because they were anti-dilutive. Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Cash FlowsFor the Three Months EndedMarch 31, 2011June 30, 2011RMBRMBUS$(in thousands)Cash flow from operating activities:Net income
16,09535,7285,528Adjustments to reconcile net income to net cash provided
by operating activities:Exchange loss
3,2161,180183Depreciation and amortization of property, plant
5,5105,501851Amortization of intangible assets
48,18547,6777,376Non-cash interest expense on convertible notes
1,387990153Amortization of convertible notes issuance costs
4,1504,007620Amortization of share lending costs
2,3862,343363Stock compensation expense
8,5197,8261,212Land use rights expense
47487Loss on disposal of property, plant and equipment
30416Deferred income taxes
6,6607,3891,143Gain on repurchase of convertible notes
(1,570)(4,112)(637)Provision for allowance for doubtful accounts
6,0202,367366Changes in operating assets and liabilities:Trade accounts receivable
(89,377)(86,332)(13,357)Prepayments and other receivables
257,0731,094Accrued liabilities and other payables
19,65215,7282,433Income taxes payable
14,09513,9852,164Net cash provided by operating activities37,33962,2439,630Cash flow from investing activities:Purchase of property, plant and equipment
(737)(656)(102)Purchase of intangible assets
(274)--Proceeds from sale of HIFU business
19,80097,35815,063Net cash provided by investing activities18,78996,70214,961Cash flow from financing activities:Payment for repurchase of convertible notes
(41,670)(41,621)(6,439)Prepayment for repurchase of convertible notes
(4,127)--Payment for transaction cost for issuance of convertible notes
(1,647)--Payment for high yield note offering expenses
(1,477)--Net cash used in financing activities(48,921)(41,621)(6,439)Effect of foreign currency exchange rate change on cash
and cash equivalents
(2,773)(1,684)(260)Net increase in cash and cash equivalents4,434115,64017,892Cash and cash equivalents at beginning of period
1,119,3841,123,818173,871Cash and cash equivalents at end of period1,123,8181,239,458191,763China Medical Technologies, Inc.EBITDA and Adjusted EBITDAMeasuresFor the Three Months EndedJune 30, 2010June 30, 2011RMBRMBUS$(in thousands)Net income
(4,597)(7,336)(1,135)Interest expense – convertible notes
32,50533,3475,159Interest expense – amortization of convertible
notes issuance costs
4,0124,007620Interest expense – amortization of share
2,4752,343363Income tax expense
141,953150,57523,296Adjustments:Stock compensation expense
10,5927,8261,212Gain on repurchase of convertible notes
(47,393)(4,112)(637)Adjusted EBITDA (3)
105,152154,28923,871Notes:(1) EBIT represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense and income tax expense.(2) EBITDA represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense, income tax expense, depreciation and amortization.(3) Adjusted EBITDA represents EBITDA excluding the effects of stock compensation expense and gain on repurchase of convertible notes.
|SOURCE China Medical Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved